This report provides a comprehensive analysis of the global Sartan-series drugs market, focusing on angiotensin II receptor antagonists like losartan and valsartan. It evaluates market dynamics, including key drivers and trends, while offering detailed forecasts through 2032 across various product types and applications. The study examines regional growth in the Americas, APAC, Europe, and MEA, alongside competitive landscapes featuring major industry players. Through detailed segmentation, the report identifies emerging opportunities and strategic shifts within the global antihypertensive pharmaceutical sector.

Market Overview

The global Sartan-series Drugs market is projected to experience significant growth from 2025 through 2032, expanding at a steady compound annual growth rate over the forecast period.

Sartan-series drugs are commonly used clinical antihypertensive medications characterized by the suffix "sartan." These drugs are also known as angiotensin II receptor antagonists or Angiotensin receptor blockers (ARBs). Examples include losartan, valsartan, telmisartan, irbesartan, and candesartan. Any medicine with a name ending in 'sartan' is classified as an ARB.

Regional Market Analysis

Global Outlook

The global Sartan-series Drugs market is expected to show consistent expansion between 2025 and 2032.

United States

The United States market for Sartan-series Drugs is estimated to increase from 2025 through 2032, maintaining a positive compound annual growth rate.

China

The China market for Sartan-series Drugs is estimated to increase from 2025 through 2032, maintaining a positive compound annual growth rate.

Europe

The Europe market for Sartan-series Drugs is estimated to increase from 2025 through 2032, maintaining a positive compound annual growth rate.

Market Segmentation

By Type

• Losartan
• Valsartan
• Irbesartan
• Telmisartan
• Olmesartan
• Candesartan
• Sacubitril/valsartan
• Others

By Application

• Hospital Pharmacy
• Retail Pharmacy

By Region

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

Competitive Landscape

Key Players

The following companies have been profiled based on primary expert input and analysis of their company coverage, product portfolios, and market penetration:

• Novartis
• Merck & Co
• Sanofi
• Pfizer
• Bayer
• AstraZeneca
• Daiichi Sankyo
• Takeda
• Bristol-Myers Squibb Company
• Boehringer Ingelheim
• Abbott
• Teva Pharmaceutical
• Shenzhen Salubris Pharmaceuticals

Market Share and Strategy

Global key players include Novartis, Merck & Co, Sanofi, Pfizer, and Bayer. In 2025, the two largest companies in the global market are expected to hold a significant portion of the total market share.

This report analyzes the strategies of leading global companies, focusing on their Sartan-series Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints to understand their unique positions in an accelerating global market.

Report Scope and Methodology

Research Content

LPI (LP Information)'s newest research report, the “Sartan-series Drugs Industry Forecast,” reviews total world Sartan-series Drugs sales in 2025. It provides a comprehensive analysis by region and market sector of projected Sartan-series Drugs sales for 2026 through 2032. The report includes detailed sales breakdowns by region, market sector, and sub-sector, provided in US$ millions.

Key Insights and Trends

This Insight Report provides a comprehensive analysis of the global Sartan-series Drugs landscape, highlighting key trends related to:

• Product segmentation
• Company formation
• Revenue
• Market share
• Latest developments
• M&A activity

The report evaluates key market trends, drivers, and affecting factors shaping the global outlook. It breaks down the forecast by Type, Application, Geography, and Market Size to highlight emerging pockets of opportunity.

Methodology

The study utilizes a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, offering a highly nuanced view of the current state and future trajectory of the global Sartan-series Drugs industry. The report presents a comprehensive overview of market shares and growth opportunities by product type, application, key players, and key regions and countries.

• 1 Scope of the Report

  • 1.1 Market Introduction

  • 1.2 Years Considered

  • 1.3 Research Objectives

  • 1.4 Market Research Methodology

  • 1.5 Research Process and Data Source

  • 1.6 Economic Indicators

  • 1.7 Currency Considered

  • 1.8 Market Estimation Caveats

• 2 Executive Summary

  • 2.1 World Market Overview

    • 2.1.1 Global Sartan-series Drugs Market Size (2021-2032)

    • 2.1.2 Sartan-series Drugs Market Size CAGR by Region (2021 VS 2025 VS 2032)

    • 2.1.3 World Current & Future Analysis for Sartan-series Drugs by Country/Region (2021, 2025 & 2032)

  • 2.2 Sartan-series Drugs Segment by Type

    • 2.2.1 Losartan

    • 2.2.2 Valsartan

    • 2.2.3 Irbesartan

    • 2.2.4 Telmisartan

    • 2.2.5 Olmesartan

    • 2.2.6 Candesartan

    • 2.2.7 Sacubitril/valsartan

    • 2.2.8 Others

    • 2.2.9 Sartan-series Drugs Market Size by Type

      • 2.2.9.1 Sartan-series Drugs Market Size CAGR by Type (2021 VS 2025 VS 2032)
      • 2.2.9.2 Global Sartan-series Drugs Market Size Market Share by Type (2021-2026)

  • 2.3 Sartan-series Drugs Segment by Application

    • 2.3.1 Hospital Pharmaty

    • 2.3.2 Retail Pharmacy

    • 2.3.3 Sartan-series Drugs Market Size by Application

      • 2.3.3.1 Sartan-series Drugs Market Size CAGR by Application (2021 VS 2025 VS 2032)
      • 2.3.3.2 Global Sartan-series Drugs Market Size Market Share by Application (2021-2026)

• 3 Sartan-series Drugs Market Size by Player

  • 3.1 Sartan-series Drugs Market Size Market Share by Player

    • 3.1.1 Global Sartan-series Drugs Revenue by Player (2021-2026)

    • 3.1.2 Global Sartan-series Drugs Revenue Market Share by Player (2021-2026)

  • 3.2 Global Sartan-series Drugs Key Players Head office and Products Offered

  • 3.3 Market Concentration Rate Analysis

    • 3.3.1 Competition Landscape Analysis

    • 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

  • 3.4 New Products and Potential Entrants

  • 3.5 Mergers & Acquisitions, Expansion

• 4 Sartan-series Drugs by Region

  • 4.1 Sartan-series Drugs Market Size by Region (2021-2026)

  • 4.2 Global Sartan-series Drugs Annual Revenue by Country/Region (2021-2026)

  • 4.3 Americas Sartan-series Drugs Market Size Growth (2021-2026)

  • 4.4 APAC Sartan-series Drugs Market Size Growth (2021-2026)

  • 4.5 Europe Sartan-series Drugs Market Size Growth (2021-2026)

  • 4.6 Middle East & Africa Sartan-series Drugs Market Size Growth (2021-2026)

• 5 Americas

  • 5.1 Americas Sartan-series Drugs Market Size by Country (2021-2026)

  • 5.2 Americas Sartan-series Drugs Market Size by Type (2021-2026)

  • 5.3 Americas Sartan-series Drugs Market Size by Application (2021-2026)

  • 5.4 United States

  • 5.5 Canada

  • 5.6 Mexico

  • 5.7 Brazil

• 6 APAC

  • 6.1 APAC Sartan-series Drugs Market Size by Region (2021-2026)

  • 6.2 APAC Sartan-series Drugs Market Size by Type (2021-2026)

  • 6.3 APAC Sartan-series Drugs Market Size by Application (2021-2026)

  • 6.4 China

  • 6.5 Japan

  • 6.6 South Korea

  • 6.7 Southeast Asia

  • 6.8 India

  • 6.9 Australia

• 7 Europe

  • 7.1 Europe Sartan-series Drugs Market Size by Country (2021-2026)

  • 7.2 Europe Sartan-series Drugs Market Size by Type (2021-2026)

  • 7.3 Europe Sartan-series Drugs Market Size by Application (2021-2026)

  • 7.4 Germany

  • 7.5 France

  • 7.6 UK

  • 7.7 Italy

  • 7.8 Russia

• 8 Middle East & Africa

  • 8.1 Middle East & Africa Sartan-series Drugs by Region (2021-2026)

  • 8.2 Middle East & Africa Sartan-series Drugs Market Size by Type (2021-2026)

  • 8.3 Middle East & Africa Sartan-series Drugs Market Size by Application (2021-2026)

  • 8.4 Egypt

  • 8.5 South Africa

  • 8.6 Israel

  • 8.7 Turkey

  • 8.8 GCC Countries

• 9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers & Growth Opportunities

  • 9.2 Market Challenges & Risks

  • 9.3 Industry Trends

• 10 Global Sartan-series Drugs Market Forecast

  • 10.1 Global Sartan-series Drugs Forecast by Region (2027-2032)

    • 10.1.1 Global Sartan-series Drugs Forecast by Region (2027-2032)

    • 10.1.2 Americas Sartan-series Drugs Forecast

    • 10.1.3 APAC Sartan-series Drugs Forecast

    • 10.1.4 Europe Sartan-series Drugs Forecast

    • 10.1.5 Middle East & Africa Sartan-series Drugs Forecast

  • 10.2 Americas Sartan-series Drugs Forecast by Country (2027-2032)

    • 10.2.1 United States Market Sartan-series Drugs Forecast

    • 10.2.2 Canada Market Sartan-series Drugs Forecast

    • 10.2.3 Mexico Market Sartan-series Drugs Forecast

    • 10.2.4 Brazil Market Sartan-series Drugs Forecast

  • 10.3 APAC Sartan-series Drugs Forecast by Region (2027-2032)

    • 10.3.1 China Sartan-series Drugs Market Forecast

    • 10.3.2 Japan Market Sartan-series Drugs Forecast

    • 10.3.3 Korea Market Sartan-series Drugs Forecast

    • 10.3.4 Southeast Asia Market Sartan-series Drugs Forecast

    • 10.3.5 India Market Sartan-series Drugs Forecast

    • 10.3.6 Australia Market Sartan-series Drugs Forecast

  • 10.4 Europe Sartan-series Drugs Forecast by Country (2027-2032)

    • 10.4.1 Germany Market Sartan-series Drugs Forecast

    • 10.4.2 France Market Sartan-series Drugs Forecast

    • 10.4.3 UK Market Sartan-series Drugs Forecast

    • 10.4.4 Italy Market Sartan-series Drugs Forecast

    • 10.4.5 Russia Market Sartan-series Drugs Forecast

  • 10.5 Middle East & Africa Sartan-series Drugs Forecast by Region (2027-2032)

    • 10.5.1 Egypt Market Sartan-series Drugs Forecast

    • 10.5.2 South Africa Market Sartan-series Drugs Forecast

    • 10.5.3 Israel Market Sartan-series Drugs Forecast

    • 10.5.4 Turkey Market Sartan-series Drugs Forecast

  • 10.6 Global Sartan-series Drugs Forecast by Type (2027-2032)

  • 10.7 Global Sartan-series Drugs Forecast by Application (2027-2032)

    • 10.7.1 GCC Countries Market Sartan-series Drugs Forecast

• 11 Key Players Analysis

  • 11.1 Novartis

    • 11.1.1 Novartis Company Information

    • 11.1.2 Novartis Sartan-series Drugs Product Offered

    • 11.1.3 Novartis Sartan-series Drugs Revenue, Gross Margin and Market Share (2021-2026)

    • 11.1.4 Novartis Main Business Overview

    • 11.1.5 Novartis Latest Developments

  • 11.2 Merck & Co

    • 11.2.1 Merck & Co Company Information

    • 11.2.2 Merck & Co Sartan-series Drugs Product Offered

    • 11.2.3 Merck & Co Sartan-series Drugs Revenue, Gross Margin and Market Share (2021-2026)

    • 11.2.4 Merck & Co Main Business Overview

    • 11.2.5 Merck & Co Latest Developments

  • 11.3 Sanofi

    • 11.3.1 Sanofi Company Information

    • 11.3.2 Sanofi Sartan-series Drugs Product Offered

    • 11.3.3 Sanofi Sartan-series Drugs Revenue, Gross Margin and Market Share (2021-2026)

    • 11.3.4 Sanofi Main Business Overview

    • 11.3.5 Sanofi Latest Developments

  • 11.4 Pfizer

    • 11.4.1 Pfizer Company Information

    • 11.4.2 Pfizer Sartan-series Drugs Product Offered

    • 11.4.3 Pfizer Sartan-series Drugs Revenue, Gross Margin and Market Share (2021-2026)

    • 11.4.4 Pfizer Main Business Overview

    • 11.4.5 Pfizer Latest Developments

  • 11.5 Bayer

    • 11.5.1 Bayer Company Information

    • 11.5.2 Bayer Sartan-series Drugs Product Offered

    • 11.5.3 Bayer Sartan-series Drugs Revenue, Gross Margin and Market Share (2021-2026)

    • 11.5.4 Bayer Main Business Overview

    • 11.5.5 Bayer Latest Developments

  • 11.6 AstraZeneca

    • 11.6.1 AstraZeneca Company Information

    • 11.6.2 AstraZeneca Sartan-series Drugs Product Offered

    • 11.6.3 AstraZeneca Sartan-series Drugs Revenue, Gross Margin and Market Share (2021-2026)

    • 11.6.4 AstraZeneca Main Business Overview

    • 11.6.5 AstraZeneca Latest Developments

  • 11.7 Daiichi Sankyo

    • 11.7.1 Daiichi Sankyo Company Information

    • 11.7.2 Daiichi Sankyo Sartan-series Drugs Product Offered

    • 11.7.3 Daiichi Sankyo Sartan-series Drugs Revenue, Gross Margin and Market Share (2021-2026)

    • 11.7.4 Daiichi Sankyo Main Business Overview

    • 11.7.5 Daiichi Sankyo Latest Developments

  • 11.8 Takeda

    • 11.8.1 Takeda Company Information

    • 11.8.2 Takeda Sartan-series Drugs Product Offered

    • 11.8.3 Takeda Sartan-series Drugs Revenue, Gross Margin and Market Share (2021-2026)

    • 11.8.4 Takeda Main Business Overview

    • 11.8.5 Takeda Latest Developments

  • 11.9 Bristol-Myers Squibb Company

    • 11.9.1 Bristol-Myers Squibb Company Company Information

    • 11.9.2 Bristol-Myers Squibb Company Sartan-series Drugs Product Offered

    • 11.9.3 Bristol-Myers Squibb Company Sartan-series Drugs Revenue, Gross Margin and Market Share (2021-2026)

    • 11.9.4 Bristol-Myers Squibb Company Main Business Overview

    • 11.9.5 Bristol-Myers Squibb Company Latest Developments

  • 11.10 Boehringer Ingelheim

    • 11.10.1 Boehringer Ingelheim Company Information

    • 11.10.2 Boehringer Ingelheim Sartan-series Drugs Product Offered

    • 11.10.3 Boehringer Ingelheim Sartan-series Drugs Revenue, Gross Margin and Market Share (2021-2026)

    • 11.10.4 Boehringer Ingelheim Main Business Overview

    • 11.10.5 Boehringer Ingelheim Latest Developments

  • 11.11 Abbott

    • 11.11.1 Abbott Company Information

    • 11.11.2 Abbott Sartan-series Drugs Product Offered

    • 11.11.3 Abbott Sartan-series Drugs Revenue, Gross Margin and Market Share (2021-2026)

    • 11.11.4 Abbott Main Business Overview

    • 11.11.5 Abbott Latest Developments

  • 11.12 Teva Pharmaceutical

    • 11.12.1 Teva Pharmaceutical Company Information

    • 11.12.2 Teva Pharmaceutical Sartan-series Drugs Product Offered

    • 11.12.3 Teva Pharmaceutical Sartan-series Drugs Revenue, Gross Margin and Market Share (2021-2026)

    • 11.12.4 Teva Pharmaceutical Main Business Overview

    • 11.12.5 Teva Pharmaceutical Latest Developments

  • 11.13 Shenzhen Salubris Pharmaceuticals

    • 11.13.1 Shenzhen Salubris Pharmaceuticals Company Information

    • 11.13.2 Shenzhen Salubris Pharmaceuticals Sartan-series Drugs Product Offered

    • 11.13.3 Shenzhen Salubris Pharmaceuticals Sartan-series Drugs Revenue, Gross Margin and Market Share (2021-2026)

    • 11.13.4 Shenzhen Salubris Pharmaceuticals Main Business Overview

    • 11.13.5 Shenzhen Salubris Pharmaceuticals Latest Developments

• 12 Research Findings and Conclusion